BACKGROUND: Dysfunctional adipose tissue plays an important role in the etiology of the metabolic syndrome, type 2 diabetes, and dyslipidemia. However, the molecular mechanisms underlying adipocyte dysfunction are incompletely understood. AIM: The aim of the study was to identify differentially regulated pathways in sc adipocytes of dyslipidemic subjects. METHODS: Whole-genome expression profiling was conducted on sc adipocytes from a discovery group of nine marginally overweight subjects with familial combined hyperlipidemia (FCHL) and nine controls of comparable body sizes as well as two independent confirmation groups. In this study, FCHL served as a model of familial insulin resistance and dyslipidemia, in the absence of frank obesity. RESULTS: Functional analyses and gene set enrichment analysis using the Kyoto Encyclopedia of Genes and Genomes or a custom pathway database identified the complement system and complement regulators as one of the top up-regulated pathways in FCHL [false discovery rate (FDR) < 1E-30]. Higher adipocyte complement expression in FCHL was confirmed in the appropriate confirmation group. Higher complement gene expression was associated with lower adipocyte insulin receptor substrate-1 expression as marker of adipocyte insulin resistance, independent of age, sex, or disease status, and this association was corroborated in the two confirmation groups. Additionally, complement gene expression was associated with triglycerides in the discovery set and with triglycerides and/or waist circumference in the confirmation groups. Complement pathway up-regulation did not appear to be driven by hypertriglyceridemia because a 40% pharmacological reduction in triglycerides did not affect complement expression. CONCLUSIONS: These findings point to an up-regulation of a complement-related transcriptome in sc adipocytes under metabolically stressed conditions, even in the absence of overt obesity. Such up-regulation may subsequently influence downstream processes, including macrophage infiltration into adipose tissue and adipocyte insulin resistance.
BACKGROUND: Dysfunctional adipose tissue plays an important role in the etiology of the metabolic syndrome, type 2 diabetes, and dyslipidemia. However, the molecular mechanisms underlying adipocyte dysfunction are incompletely understood. AIM: The aim of the study was to identify differentially regulated pathways in sc adipocytes of dyslipidemic subjects. METHODS: Whole-genome expression profiling was conducted on sc adipocytes from a discovery group of nine marginally overweight subjects with familial combined hyperlipidemia (FCHL) and nine controls of comparable body sizes as well as two independent confirmation groups. In this study, FCHL served as a model of familial insulin resistance and dyslipidemia, in the absence of frank obesity. RESULTS: Functional analyses and gene set enrichment analysis using the Kyoto Encyclopedia of Genes and Genomes or a custom pathway database identified the complement system and complement regulators as one of the top up-regulated pathways in FCHL [false discovery rate (FDR) < 1E-30]. Higher adipocyte complement expression in FCHL was confirmed in the appropriate confirmation group. Higher complement gene expression was associated with lower adipocyte insulin receptor substrate-1 expression as marker of adipocyte insulin resistance, independent of age, sex, or disease status, and this association was corroborated in the two confirmation groups. Additionally, complement gene expression was associated with triglycerides in the discovery set and with triglycerides and/or waist circumference in the confirmation groups. Complement pathway up-regulation did not appear to be driven by hypertriglyceridemia because a 40% pharmacological reduction in triglycerides did not affect complement expression. CONCLUSIONS: These findings point to an up-regulation of a complement-related transcriptome in sc adipocytes under metabolically stressed conditions, even in the absence of overt obesity. Such up-regulation may subsequently influence downstream processes, including macrophage infiltration into adipose tissue and adipocyte insulin resistance.
Authors: M C G J Brouwers; C J H van der Kallen; N C Schaper; M M J van Greevenbroek; C D A Stehouwer Journal: Neth J Med Date: 2010-04 Impact factor: 1.422
Authors: A Muscari; C Bozzoli; G M Puddu; Z Sangiorgi; A Dormi; C Rovinetti; G C Descovich; P Puddu Journal: Am J Med Date: 1995-04 Impact factor: 4.965
Authors: M Dolinková; I Dostálová; Z Lacinová; D Michalský; D Haluzíková; M Mráz; M Kasalický; M Haluzík Journal: Mol Cell Endocrinol Date: 2008-05-09 Impact factor: 4.102
Authors: José María Moreno-Navarrete; Rubén Martínez-Barricarte; Victoria Catalán; Mònica Sabater; Javier Gómez-Ambrosi; Francisco José Ortega; Wifredo Ricart; Mathias Blüher; Gema Frühbeck; Santiago Rodríguez de Cordoba; José Manuel Fernández-Real Journal: Diabetes Date: 2009-10-15 Impact factor: 9.461
Authors: Sonia I Vlaicu; Alexandru Tatomir; Dallas Boodhoo; Stefan Vesa; Petru A Mircea; Horea Rus Journal: Immunol Res Date: 2016-06 Impact factor: 2.829
Authors: Marina Barreto Felisbino; Mark Ziemann; Ishant Khurana; Jun Okabe; Keith Al-Hasani; Scott Maxwell; K N Harikrishnan; Camila Borges Martins de Oliveira; Maria Luiza S Mello; Assam El-Osta Journal: Sci Rep Date: 2021-01-25 Impact factor: 4.379
Authors: Abderrazak Kitsy; Skyla Carney; Juan C Vivar; Megan S Knight; Mildred A Pointer; Judith K Gwathmey; Sujoy Ghosh Journal: PLoS One Date: 2014-07-22 Impact factor: 3.240
Authors: Daniel Castellano-Castillo; Isabel Moreno-Indias; Jose Carlos Fernandez-Garcia; Mercedes Clemente-Postigo; Manuel Castro-Cabezas; Francisco José Tinahones; María Isabel Queipo-Ortuño; Fernando Cardona Journal: Genes (Basel) Date: 2018-08-13 Impact factor: 4.096